

Japan Office

USA Office

For in vitro research use only
 Storage temperature : 2-8°C

www.htrf.com

HTRF® package insert General information

Document reference : 62ADPPEB rev06 (April 2010)

Packaging details :


		384-well low volume plate (20 µL)
62ADPPEB	HTRF® TRANSCREENER® ADP	1,000 tests

Be careful! Modification of cryptate conjugate reconstitution process (refer to S2)

1. Assay description and intended use

HTRF® TRANSCREENER® ADP is a generic method for detection of ADP.

The assay can be used for any enzyme class that produces ADP (Kinases, ATPases,..). Kinases catalyze the transfer of a phosphate group from ATP to a protein, peptide, lipid, or small molecule substrate. As well as this phosphorylated substrate, the reaction generates ADP. For ATPases, a phosphate group from ATP is transferred to a water molecule. The HTRF® TRANSCREENER® ADP assay applies to both kinase and ATPase activity assessment. The assay involves the two steps described below:




1.1. Enzymatic step:

For KINASES: During this step, the substrate is incubated with the kinase. ATP is added to start the enzymatic reaction and the kinase phosphorylates the substrate.

For ATPases: During this step the ATPase will convert the ATP into ADP and inorganic phosphate.

1.2. Universal detection step:

The detection method is based on an antibody specific to ADP labeled with Eu³⁺-Cryptate, which competes with both native ADP and d2-coupled ADP. The resulting TR-FRET signal is inversely proportional to the concentration of ADP in the calibrator or in the sample. The anti-ADP antibody labeled with Eu³⁺-Cryptate and the ADP-d2 are added with EDTA, in order to stop the kinase activity.



2. Reagent description – Stock solution preparation

Components	Quantity
ADP calibrator	1 vial lyophilized
ADP-d2	1 vial lyophilized
Anti-ADP Cryptate	1 vial lyophilized
HTRF® TRANSCREENER® ADP enzymatic buffer 5X HEPES 250mM (pH7.0), NaN3 0.1%, BSA0.05%	1 vial of 10 ml
HTRF® TRANSCREENER® ADP detection buffer Buffer supplemented with BSA 0.1%, KF 0.4M, EDTA 60mM	1 vial of 13 ml



Stock solutions to prepare
Reconstitute with distilled water (refer to product label) to obtain a 1mM stock solution
Reconstitute with 5 mL of HTRF® TRANSCREENER® ADP detection buffer to get a ready to use solution
Reconstitute with 2 mL of ADP detection buffer Transfer the 2 mL solution into another vial and add 3 mL of ADP detection buffer

Storage: All kit components must be stored at +4°C until the expiration date printed on the product label.

After reconstitution, the stock solutions can be stored 3 days at 2-8° or dispensed into single use aliquots and stored at -20°C.

3. Additional material required (not provided)

Enzymatic buffer supplements: The enzymatic buffer must be supplemented with any components required by the kinase or ATPase of interest.

	Recommended Supplier*	Stock solution to prepare
ATP	Sigma # A7699	1 mM in distilled water
Sodium Orthovanadate**	Sigma # S6508	
DTT	Sigma # D0632	100 mM in distilled water
MgCl2	Sigma # M1028	1 M (ready to use)
MnCl2	Sigma # M1787	1 M (ready to use)


* Suppliers' names are indicative

** Or other phosphatase inhibitors

Storage: Stock solutions of ATP and DTT should be aliquoted and stored at -20°C for additional use.

4. Assay protocol for 384 well low-volume plate (20µL)

Add assay components (working solutions) in the following order:



The enzymatic reaction (Step 1) is stopped by the addition of the ADP detection reagents which contain EDTA (step 2). The incubation period for the enzymatic step is optimized depending on the enzyme.

For a 384w low-volume plate, we recommend the 10 µL for the enzymatic step and the 10 µL for the detection step for a final assay volume of 20 µL. For a 96 half-well plate (100 µL), each addition volume is simply multiplied by 5.

* For low volume compound addition, adjust volume to 4 µl with 1x enzymatic buffer-Keep DMSO < 2% in the enzymatic step.

5. Preparation of the working solutions

The working solutions are prepared from stock solutions by following the instructions :

Buffer to prepare	
Enzymatic buffer	Prepare "enzymatic buffer 1X" by diluting 1 volume of Transcreener® ADP enzymatic buffer 5X with 4 volumes of distilled water and any supplements required by the enzyme of interest, i.e. phosphatase inhibitors, DTT, MgCl ₂ , MnCl ₂ , etc...
Detection buffer	Ready to use Transcreener® ADP detection buffer

Working solutions to prepare	
Compounds	Dilute compound stock solution with enzymatic buffer to prepare a working solution which has 2.5X the required final concentration for the enzymatic step .
Substrate	Dilute the substrate stock solution with enzymatic buffer to prepare a working solution which has 5X the required final concentration for the enzymatic step
Enzyme	Dilute the kinase stock solution with enzymatic buffer to prepare a working solution .
ADP	Dilute the ADP stock solution with enzymatic buffer to prepare a working solution (refer to standard curve preparation in § 6).
ATP	Dilute the ATP stock solution with enzymatic buffer to prepare a working solution (refer to standard curve preparation in § 6).
ADP-d2	Ready to use working solution
Anti ADP-Cryptate	Ready to use working solution

Precautions:

- It is recommended to prepare the required amount of enzymatic buffer 1X (supplemented with ions, components required by the enzyme of interest) just before use, as DTT is stable only one day at 2-8°C once diluted in the enzymatic buffer .
- ATP, substrate and enzyme working solutions must be kept in an ice bath for the time of the experiment (to avoid degradation). They can not be stored and must be used immediately.
- HTRF® detection reagent concentrations have been set for optimal assay performances. Note that any dilution or improper use of the detection reagents will impair the assay quality.

6. ADP/ATP Standard Curve preparations

The Standard curves mimic a kinase/ATPase reaction (as ADP is produced, ATP is depleted). The adenosine total concentration should remain constant throughout the range studied i.e. [ATP]+[ADP].

Standard curves should be performed with the concentration of ATP used for the assay.

Standard curves are given as examples for 2 different ATP concentrations: ATP 100µM and ATP 10µM.

It is recommended not to use concentrations of ATP above 100µM. If the enzyme requires to work above 100µM, please contact our technical support.

ADP standard max solutions are prepared respectively at ADP 100 µM and ADP 10µM then diluted in ATP solutions as shown below.

Standard Curve for ATP 100µM

	Standard preparation		Working concentrations			
			ADP (µM)	/	ATP (µM)	% ATP Conversion
Standard 7	100µl ADP 100µM		100	/	0	100
Standard 6	50µL	Standard 7 +	33.33	/	66.67	33.33
Standard 5	50µL	Standard 6 +	11.11	/	88.89	11.11
Standard 4	50µL	Standard 5 +	3.70	/	96.30	3.70
Standard 3	50µL	Standard 4 +	1.23	/	98.77	1.23
Standard 2	50µL	Standard 3 +	0.41	/	99.59	0.41
Standard 1	50µL	Standard 2 +	0.14	/	99.86	0.14
Standard 0	100µl ATP 100µM		0	/	100	0

Standard Curve for ATP 10µM

	Standard preparation		Working concentrations			
			ADP (µM)	/	ATP (µM)	% ATP Conversion
Standard 6	100µl ADP 10µM		10	/	0	100
Standard 5	50µL	Standard 6 +	3.33	/	6.67	33.33
Standard 4	50µL	Standard 5 +	1.11	/	8.89	11.11
Standard 3	50µL	Standard 4 +	0.37	/	9.63	3.70
Standard 2	50µL	Standard 3 +	0.12	/	9.88	1.23
Standard 1	50µL	Standard 2 +	0.04	/	9.96	0.4
Standard 0	100µl ATP 10µM		0	/	10	0

7. Detailed protocol

The enzyme assay is performed as described below, using different controls:

Negative Control (Std 0): 0% ATP Conversion (No Enzyme). This control consists of the ADP antibody-Cryptate and ADP-d2 in the presence of enzymatic reaction components (without enzyme) and ATP (0% ADP). This control defines the upper limit of the assay window. Appropriate negative control must be prepared for each ATP concentration tested.

Buffer control: used to make sure that buffers are not contaminated by Cryptate and do not generate any background fluorescence.

Cryptate control: used to check the Cryptate signal at 620 nm and for the calculation of delta F. This control defines the lower limit of the assay window.

	Standard Curve	KINASE assay		ATPase assay		Blank controls	
Enzymatic step (10µL)	Standard	Negative control	Sample	Negative control	Sample	Cryptate Control	Buffer Control
Standard	10µL						
Compounds (or enzymatic buffer)		4µL	4µL	4µL	4µL	10 µL enzymatic buffer	10 µL enzymatic buffer
Substrate		2 µL	2 µL				
Kinase / ATPase		2µL enzymatic buffer	2µL	4 µL enzymatic buffer	4µL		
ATP		2 µL	2 µL	2 µL	2 µL		

Seal plate and incubate at room temperature (RT) or 37°C

Detection step (10µL)							
ADP-d2	5 µL	5 µL	5 µL	5 µL	5 µL	5 µL detection buffer	5µL detection buffer
anti ADP-Cryptate	5 µL	5 µL	5 µL	5 µL	5 µL	5 µL	5µL detection buffer

Seal plate and incubate 1h at RT

Remove plate sealer and read on an HTRF* compatible reader*

* More information at http://www.htrf.com/technology/htrfmeasurement/compatible_readers/

8. Data reduction

The tables below present the results obtained with the standard protocol in 20µL. Results are calculated from the 665nm/620nm ratio and expressed in Delta F. Two examples of standard curves for 100µM and 10µM of ADP/ATP are given in the tables below.

The fluorescence is measured at 620 nm (Cryptate) and 665 nm (d2).

A ratio is calculated (665/620) for each well.

Results are expressed as follows (readout on PHERAstar Plus reader from BMG LABTECH):



100µM ADP/ATP Standard Curve Data

			A (665nm)	B (620nm)	ratio (1)	Mean ratio (2)	CV% (3)	Delta F% (4)	1-(dF/dFmax) (5)
		Blank (Cryptate control)	1443 1319	28031 25785	515 512	513	0.4		
	% ATP Conversion	ADP (µM) / ATP (µM) working concentrations							
Standard 0	0	0 µM / 100µM	28253 29603	26895 26238	10505 11282	10894	5.0	2023	
Standard 1	0.14	0.14 µM / 99.86µM	23995 26282	24858 27055	9653 9714	9684	0.4	1787	12%
Standard 2	0.41	0.41 µM / 99.59µM	23796 22232	27318 27256	8711 8157	8434	4.6	1543	24%
Standard 3	1.23	1.23 µM / 98.77µM	16211 17393	26587 29106	6097 5976	6037	1.4	1076	47%
Standard 4	3.70	3.7 µM / 96.3µM	8771 10641	24479 29027	3583 3666	3624	1.6	606	70%
Standard 5	11.11	11.1 µM / 88.9µM	5055 5812	24747 28680	2043 2026	2035	0.6	296	85%
Standard 6	33.33	33.3 µM / 66.7µM	3690 3551	27177 28692	1358 1238	1298	6.5	153	92%
Standard 7	100	100 µM / 0µM	2296 2501	24598 26149	933 956	945	1.7	84	96%

10μM ADP/ATP Standard Curve Data

			A (665nm)	B (620nm)	ratio (1)	Mean ratio (2)	CV% (3)	Delta F% (4)	1-(dF/dFmax) (5)
		Blank (Cryptate control)	1249 1196	22647 22593	552 529	540	2.9		
	% ATP Conversion	ADP (μM) / ATP (μM) working concentrations							
Standard 0	0	0 μM / 10μM	37945 33962	18674 16901	20320 20095	20207	0.8	3639	
Standard 1	0.4	0.04μM / 9.96μM	37857 35845	19950 18823	18976 19043	19010	0.3	3417	6%
Standard 2	1.23	0.12 μM / 9.88μM	34250 34001	19222 19351	17818 17571	17694	1.0	3174	13%
Standard 3	3.70	0.37 μM / 9.63μM	31518 29293	22213 20794	14189 14087	14138	0.5	2516	31%
Standard 4	11.11	1.11 μM / 8.89μM	19535 19044	21053 21313	9279 8935	9107	2.07	1585	56%
Standard 5	33.33	3.33 μM / 6.67μM	10188 10704	20953 22356	4862 4788	4825	1.1	793	78%
Standard 6	100	10 μM / 0μM	5653 4940	23375 20323	2418 2431	2425	0.4	349	90%

- Ratio = (665 nm/620 nm) x 104
- Mean ratio = Σ ratio / 2 for n=2
- CV% = (Std deviation/Mean ratio) x 100
- Delta F% = (ratio - ratioBlank) / ratioBlank x 100
Delta Fmax = Delta F of the negative control (standard)
- In order to obtain positive modulation, data can be expressed as follows: 1-(Delta Fsample / Delta Fmax)



Copyright © 2010 CIS bio international, France

HTRF®, TRACE®, and the HTRF® logo are trademarks belonging to CIS bio international. Lumi4™ is a registered trademark of Lumiphore Inc.

HTRF® products are manufactured under one or more of the following patents and foreign equivalent: EP 0 180 492 / US 4,927,923 / US 5,220,012 / US 5,432,101 - EP 0 321 353 / US 5,457,185 / US 5,534,622 / US 5,346,996 / US 5,162,508 - EP 0 539 477 / US 5,512,493 - EP 0 539 435 / US 5,627,074 - EP 0 569 496 / US 5,527,684.

CIS bio international hereby grants to those buying HTRF® products from CIS bio international or its affiliates / distributors, a worldwide, non-exclusive, royalty-free, limited license to use HTRF® technology with said products for in-house life science research only. Signal amplification and correction using HTRF® technology are covered by the following U.S. patents or patent applications and foreign equivalents: US 5,512,493 - US 5,527,684 - US 6,352,672.

U.S. Patent Application Nos. 11/137,947 and 11/353,500 and International Patent Application WO 2006/127008, WO2004/068115 applied. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) to not transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. BellBrook Labs LLC will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use, or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, BellBrook Labs LLC is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, BellBrook Labs LLC, 5500 Nobel Drive, Suite 250, Madison, Wisconsin 53711. Phone (608)443-2400. Fax (608)441-2967

Transcreener® is a trademark of BellBrook Labs.

Transcreener® HTS Assay Platform technology is patented (U.S. patent 7,332,278), and is being used under license from BellBrook Labs, LLC.
©2010 BellBrook Labs. All rights reserved